156 related articles for article (PubMed ID: 17993652)
1. 131I exhalation by patients undergoing therapy of thyroid diseases.
Gründel M; Kopka B; Schulz R
Radiat Prot Dosimetry; 2008; 129(4):435-8. PubMed ID: 17993652
[TBL] [Abstract][Full Text] [Related]
2. [Exposure of relatives of patients after stationary radioiodine therapy by inhalation of 131I in their homes].
Wellner U; Eschner W; Hillger HW; Schicha H
Nuklearmedizin; 1998 May; 37(3):113-9. PubMed ID: 9604232
[TBL] [Abstract][Full Text] [Related]
3. [Exhalation of I-131 after radioiodine therapy (RIT): time dependence and chemical form].
Schomäcker K; Fischer T; Eschner W; Gaidouk MI; Schicha H
Nuklearmedizin; 2001 Feb; 40(1):15-22. PubMed ID: 11373934
[TBL] [Abstract][Full Text] [Related]
4. Exhalation of
Sudbrock F; Fischer T; Zimmermanns B; Drzezga A; Schomäcker K
J Environ Radioact; 2017 Jan; 166(Pt 1):162-165. PubMed ID: 27405239
[TBL] [Abstract][Full Text] [Related]
5. [Measurement of incorporation in family members of radioiodine therapy patients after therapy of benign thyroid diseases].
Lassmann M; Hänscheid H; Schelper LF; Körber C; Reiners C
Nuklearmedizin; 1998 May; 37(3):120-3. PubMed ID: 9604233
[TBL] [Abstract][Full Text] [Related]
6. Exhalation of ¹³¹I after radioiodine therapy: measurements in exhaled air.
Schomäcker K; Sudbrock F; Fischer T; Dietlein M; Kobe C; Gaidouk M; Schicha H
Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2165-72. PubMed ID: 21847636
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of radioiodine in nuclear medical therapy.
Heinemann K; Vogt KJ; Friedrich W; Feinendegen LE
Strahlentherapie; 1983 Aug; 159(8):490-4. PubMed ID: 6623561
[TBL] [Abstract][Full Text] [Related]
8. [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].
Chaś J; Kowalczyk A; Siekierzyński M; Dziuk E; Janiak MK
Wiad Lek; 2001; 54 Suppl 1():312-20. PubMed ID: 12182042
[TBL] [Abstract][Full Text] [Related]
9. [Radioactivity levels of the air inhaled by personnel of a radioiodine therapy unit].
Krześniak JW; Fill H; Oberladstätter M
Nuklearmedizin; 1987 Jun; 26(3):143-6. PubMed ID: 3628023
[TBL] [Abstract][Full Text] [Related]
10. Airborne radioiodine contamination caused by 131I treatment.
Krześniak JW; Chomicki OA; Czermińska M; Górowski T
Nuklearmedizin; 1979 Dec; 18(5):246-51. PubMed ID: 547252
[TBL] [Abstract][Full Text] [Related]
11. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
[TBL] [Abstract][Full Text] [Related]
12. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
[TBL] [Abstract][Full Text] [Related]
13. [The treatment of thyroid diseases using 131I in a special ward with a liquid waste storage plant].
Wellner U; Schicha H
Nuklearmedizin; 1993 Jun; 32(3):149-55. PubMed ID: 8327334
[TBL] [Abstract][Full Text] [Related]
14. [Radioiodine therapy in Europe--a survey].
Schicha H; Scheidhauer K
Nuklearmedizin; 1993 Dec; 32(6):321-4. PubMed ID: 8295830
[TBL] [Abstract][Full Text] [Related]
15. [Is the post-therapeutic dosimetry of patients with short-term hospitalization after 131I therapy sufficiently reliable?].
Körber C; Schneider P; Hänscheid H; Köck PR; Reiners C
Nuklearmedizin; 2000; 39(1):9-12. PubMed ID: 10726251
[TBL] [Abstract][Full Text] [Related]
16. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
17. Liquid discharges from patients undergoing 131I treatments.
Barquero R; Basurto F; Nuñez C; Esteban R
J Environ Radioact; 2008 Oct; 99(10):1530-4. PubMed ID: 18243440
[TBL] [Abstract][Full Text] [Related]
18. [Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures].
Sudbrock F; Boldt F; Kobe C; Hammes J; Eschner W; Schicha H
Nuklearmedizin; 2009; 48(1):17-25. PubMed ID: 19212607
[TBL] [Abstract][Full Text] [Related]
19. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
20. Effective method of measuring the radioactivity of [ 131I]-capsule prior to radioiodine therapy with significant reduction of the radiation exposure to the medical staff.
Lützen U; Zhao Y; Marx M; Imme T; Assam I; Siebert FA; Culman J; Zuhayra M
J Appl Clin Med Phys; 2016 Jul; 17(4):59-72. PubMed ID: 27455475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
